Articles On Cyclopharm (ASX:CYC)
Title | Source | Codes | Date |
---|---|---|---|
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | CYC | 1 year ago |
OPEC oil cut gives Energy sector a big boost
ShareCafeOPEC oil cut gives Energy sector a big boost The Dow Jones Industrial Average added more than 300 points overnight, as Wall Street shows resilience despite an oil output cut from OPEC+ that threatens to sto... |
ShareCafe | CYC | 1 year ago |
Deutsche Bank the latest international bank to tumble
ShareCafeDeutsche Bank the latest international bank to tumble Stocks rose Friday after a volatile trading session. Although Friday began with fears that the banking crisis was spilling over to Deutsche Bank, the ma... |
ShareCafe | CYC | 1 year ago |
After Neuren’s success, which other ASX health stocks are knocking on the US FDA door?
Several ASX health stocks are seeking US FDA approval for drugs/devices in the near future Telix Pharmaceuticals is chasing renal cancer imaging approval for TLX-250 CDx Aroa is awaiting an FDA decision on the required regulatory pathway... |
Stockhead | CYC | 1 year ago |
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry The US FDA announced last week that:... |
Stockhead | CYC | 1 year ago |
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | CYC | 1 year ago |
Can you guess the top 3 performing All Ordinaries shares in the first week of trade?
All Ordinaries Index (ASX: XAO) shares closed up 0.7% on Friday. That helped the All Ords post a gain of 1.2% for the first week of trading in 2023. Investors will certainly welcome this start to the new year after All Ordinaries shares dr... |
Motley Fool | CYC | 1 year ago |
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | CYC | 1 year ago |
Closing Bell: It could get bearish tonight in New York as local small caps close slightly higher
ASX 200 ends flat again Small caps gain a little bit ELO, DRO and EOS rise like legends There are some mixed feelings around the neighbourhood heading into this latest gut churning measure of US inflation tonight. US futures are slightl... |
Stockhead | CYC | 1 year ago |
Closing Bell: Flat benchmark, lower small cap index cop free lesson from OpenLearning, up 50% by hump day
ASX 200 ends flat as Small caps s wee bit lower OLL investment sparks share price surge We’re pretty flat on Wednesday. I am, the benchmark is and so is Australia as a nation and a continent. Luckily Gregor Stronach, my trusty fiend on... |
Stockhead | CYC | 1 year ago |
Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice
Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re... |
Stockhead | CYC | 1 year ago |
Key week for US economic data as indexes produce strong weekly gains
ShareCafeKey week for US economic data as indexes produce strong weekly gains US equities were higher in Friday trading, finishing just off best levels. Each of the major averages were up more than 2.5 per cent for... |
ShareCafe | CYC | 1 year ago |
Biden Administration moves to ban chip sales into China
ShareCafeBiden Administration moves to ban chip sales into China The Dow Jones Industrial Average and the S&P 500 ended the first day of September on a high note as traders looked forward to the jobs report tomo... |
ShareCafe | CYC | 1 year ago |
Cyclopharm reports strong revenue growth for six months to June
Radiopharmaceutical company Cyclopharm Limited (ASX:CYC) has announced results for the six-months to the end of June. The company said the results include record consolidated group revenue of... |
BiotechDispatch | CYC | 1 year ago |
Market highlights and 5 ASX small caps to watch on Wednesday
The ASX 200 is set to open higher on Wednesday Wall Street was mixed overnight Oil is at the lowest level in six months Local shares are set to open higher today. At 8am AEST, the ASX 200 August futures contract is pointing up by 0.10%. O... |
Stockhead | CYC | 1 year ago |
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F... |
Stockhead | CYC | 1 year ago |
ASX Health Stocks: FDA to expedite submission for Botanix’s sweaty armpits gel
Botanix’s FDA submission gets accelerated Release extends contract with Medgate to use the ResAppDx platform Cyclopharm’s Technegas is used ahead of competitor products in Covid-19 diagnosis Clinical dermatology company, Botanix Pharma (A... |
Stockhead | CYC | 1 year ago |
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m... |
Stockhead | CYC | 1 year ago |
Australian Broker Call *Extra* Edition – May 19, 2022
An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au... |
FNArena | CYC | 1 year ago |
Check Up: Money managers are still bullish on Healthcare; here’s what they said
The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week Dr Anthony Faucci, America’s top infectious disea... |
Stockhead | CYC | 2 years ago |
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot... |
Stockhead | CYC | 2 years ago |
ASX set for lower opening as tech selloff drags Wall Street; Bitcoin slumps 8%
Highlights The ASX 200 index is likely to open lower on Tuesday tracking lower global equities. U.S equity markets ended sharply lower on Monday as investors sold tech shares in the wake of surging U.S. treasury yields. Bond yields ro... |
Kalkine Media | CYC | 2 years ago |
BCN, CYC, SIG, WAR, WAX: These ASX stocks will turn ex-dividend on April 4
Highlights Companies like Beacon Minerals, Cyclopharm and Sigma Healthcare will be turning ex-dividend on Monday (4 April 2022). The ex-dividend date is usually one day (business day) before the record date for stocks. Investors get t... |
Kalkine Media | CYC | 2 years ago |
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?
Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve... |
Stockhead | CYC | 2 years ago |
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month
Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal... |
Stockhead | CYC | 2 years ago |
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX
The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby... |
Stockhead | CYC | 2 years ago |
ASX Health Stocks: Clinical trials gather pace for Visioneering Tech, Anteris and other biotechs
The ASX 200 Health Index (XHJ) is falling by 0.3% at the time of writing, compared to the broader index which is down by 0.37%. Visioneering Technologies (ASX:VTI) has enrolled the first patient in its landmark international clinical trial... |
Stockhead | CYC | 2 years ago |
This ASX All Ordinaries share has defied today’s sell-off to hit a new 6-year high
The ASX is suffering today in what could be a reaction to a disastrous session in the United States. But, interestingly, one All Ordinaries Index (ASX: XAO) share has been thriving. While most of Australia slept, the Nasdaq Composite Index... |
Motley Fool | CYC | 2 years ago |
Check Up: As Omicron rages, rapid antigen testing specialist Atomo surges nearly 50pc
At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform... |
Stockhead | CYC | 2 years ago |
Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment
It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %... |
Stockhead | CYC | 2 years ago |
Healthcare has been a hot sector. Here are the top ASX biotech stocks in 2021
The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19 ravaged the world. Nasdaq-listed BioNTech, which... |
Stockhead | CYC | 2 years ago |
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables
It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont... |
Stockhead | CYC | 2 years ago |
Dr Boreham’s Crucible: Is Paul Hopper’s star power enough to get Radiopharm Theranostics beaming?
He’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radiopharm Theranostics (ASX:RAD) to his boardroom rota after the nuclear medicine play listed on the ASX on Thursday – albeit limply. The count... |
Stockhead | CYC | 2 years ago |
Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health
It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M... |
Stockhead | CYC | 2 years ago |
5 medical stocks to watch out for in 2022 -TLX, RHT, CYC, IPD, AVR
Highlights The rising population and the rise in health issues are increasing the demand for healthcare products and services. People’s lifestyle is one of the reasons for rising health issues in the present times. TLX, RHT, CYC, IPD,... |
Kalkine Media | CYC | 2 years ago |
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August
Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat... |
Stockhead | CYC | 2 years ago |
ASX Health Stocks: IDT shoots 20pc on COVID-19 deal with government, ImpediMed granted US FDA Breakthrough
IDT Australia (ASX:IDT) jumped more than 20% after announcing that it has formalised activities with the Australian Government to potentially assist with the production of a COVID-19 vaccine. There was recent media interest surrounding a mR... |
Stockhead | CYC | 2 years ago |
Market Highlights and 5 ASX Small Caps to watch on Monday
Wall Street rose ahead of world centrals banks meeting this week All three US stock market indexes bounced back on Friday, ahead of this week’s Jackson Hole Economic Policy Symposium, a virtual meeting of world central banks leaders held be... |
Stockhead | CYC | 2 years ago |
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N... |
Stockhead | CYC | 2 years ago |
ASX health stocks: EMV’s brain scanner is completed and ready for testing, stock price jumps 16pc
The ASX200 health stocks index (XHJ) fell by 0.14% this morning, compared to the broader index which rose by 0.35%. Medical imaging specialist, EMVision (ASX:EMV), has rocketed by 16% after announcing that 1st Gen portable brain scanner has... |
Stockhead | CYC | 2 years ago |
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing
The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du... |
Stockhead | CYC | 2 years ago |
Australian Broker Call *Extra* Edition – Jul 23, 2021
An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au... |
FNArena | CYC | 2 years ago |
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down
It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by Rhinomed (ASX:RNO)... |
Stockhead | CYC | 2 years ago |
Hot Money Monday: Bathurst revs up after key legal victory
Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength Index (RSI). The RSI is a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the le... |
Stockhead | CYC | 2 years ago |
Check up: A mixed bag for ASX health stocks as FDA decides fates at the flip of a coin
It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals... |
Stockhead | CYC | 2 years ago |
Hot Money Monday: Prospa comes in from the cold with six-day rally
Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength Index (RSI). The RSI is a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the le... |
Stockhead | CYC | 2 years ago |
Cyclopharm (ASX:CYC) share price jumps on trading update
Cyclopharm Limited (ASX: CYC) shares are on the rise today after the company released a trading update earlier today. In early afternoon trading, the Cyclopharm share price is trading 3.03% higher at $1.70. Shares in the company were up by... |
Motley Fool | CYC | 2 years ago |
Market Highlights and 5 ASX Small Caps to watch on Friday
Wall Street higher as US jobless claims plunged All the three major US benchmarks rose overnight, after US jobless claims fell to a new pandemic low. The Dow Jones rose by 0.38%, the S&P 500 by 0.52% to a fresh record high, while tech-f... |
Stockhead | CYC | 2 years ago |
The surge and plunge in ASX biotech shows what the FDA giveth, the FDA taketh away
Over the past month, a number of US FDA approvals have moved the share prices of global pharma stocks, including those traded here on the ASX. The biggest FDA announcement during the month came out of US-based Biogen, which received a contr... |
Stockhead | CYC | 2 years ago |
Closing Bell: Today’s biggest small cap movers on the ASX
Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scr... |
Stockhead | CYC | 2 years ago |